CA2332121A1 - Procedes pour l'inhibition d'activite tef-3 - Google Patents

Procedes pour l'inhibition d'activite tef-3 Download PDF

Info

Publication number
CA2332121A1
CA2332121A1 CA002332121A CA2332121A CA2332121A1 CA 2332121 A1 CA2332121 A1 CA 2332121A1 CA 002332121 A CA002332121 A CA 002332121A CA 2332121 A CA2332121 A CA 2332121A CA 2332121 A1 CA2332121 A1 CA 2332121A1
Authority
CA
Canada
Prior art keywords
tef
cdna
cells
binding
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002332121A
Other languages
English (en)
Inventor
Michael Howard Tindal
Richard Liqun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2332121A1 publication Critical patent/CA2332121A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés <i>in vivo</i> ou <i>in vitro</i> de sélection d'inhibiteurs d'activité TEF-3. L'invention concerne en outre des procédés permettant d'identifier des facteurs d'interaction de TEF-3. Enfin, l'invention concerne des procédés pour le traitement d'affections à médiation métalloprotéase matricielle, y compris celles du système musculo-squelettique, et du muscle cardiaque, ainsi que de maladies squelettiques liées à la croissance.
CA002332121A 1998-06-30 1999-06-30 Procedes pour l'inhibition d'activite tef-3 Abandoned CA2332121A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9131898P 1998-06-30 1998-06-30
US60/091,318 1998-06-30
PCT/US1999/014829 WO2000000161A2 (fr) 1998-06-30 1999-06-30 Procedes pour l'inhibition d'activite tef-3

Publications (1)

Publication Number Publication Date
CA2332121A1 true CA2332121A1 (fr) 2000-01-06

Family

ID=22227169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002332121A Abandoned CA2332121A1 (fr) 1998-06-30 1999-06-30 Procedes pour l'inhibition d'activite tef-3

Country Status (7)

Country Link
EP (1) EP1089794A2 (fr)
JP (1) JP2002519008A (fr)
AU (1) AU5086699A (fr)
CA (1) CA2332121A1 (fr)
IL (1) IL140058A0 (fr)
NO (1) NO20006198L (fr)
WO (1) WO2000000161A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003001906A1 (fr) * 2001-06-27 2003-01-09 Takeda Chemical Industries, Ltd. Procede de construction d'un modele animal de maladie des articulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824794A (en) * 1994-12-23 1998-10-20 Syntex (U.S.A.) Inc. Human stromelysin-1 promoter
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
EP0935753A4 (fr) * 1996-10-31 1999-12-08 Merck & Co Inc Epreuve biologique et lignee cellulaire aux fins de l'identification de mimetiques d'hormone de croissance
AU6015098A (en) * 1997-02-24 1998-09-09 Cornell Research Foundation Inc. Method of screening agents as candidates for drugs or sources of drugs

Also Published As

Publication number Publication date
JP2002519008A (ja) 2002-07-02
EP1089794A2 (fr) 2001-04-11
AU5086699A (en) 2000-01-17
WO2000000161A2 (fr) 2000-01-06
NO20006198D0 (no) 2000-12-06
IL140058A0 (en) 2002-02-10
WO2000000161A3 (fr) 2001-01-04
NO20006198L (no) 2001-02-28

Similar Documents

Publication Publication Date Title
US8187596B1 (en) Method of treating asthma or allergy by administering an IL-33 receptor antibody
JP2002504818A (ja) リガンドファミリーのｎｔｎ−２メンバー
WO2020081556A2 (fr) Complexe swi/snf non canonique et ses utilisations
US5747250A (en) Probe for tumour diagnostics or tumour therapy
US20070117138A1 (en) Splice variant cannabinoid receptor (cb1b)
JP2002523078A (ja) 新規なｉｒａｐ−ｂｐポリペプチド及び核酸分子並びにこれらの利用法
CA2332121A1 (fr) Procedes pour l&#39;inhibition d&#39;activite tef-3
JPH09506243A (ja) レセプター認識因子、蛋白配列およびその使用方法
JP2002534114A (ja) 新規ｌｒｓｇタンパク質および核酸分子ならびにそのための用途
JP4975444B2 (ja) 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
JP2002508934A (ja) Ｔｎｆレセプターに対して相同性を有する、新規な核酸およびポリペプチド
EP0888375A1 (fr) Nouvelle disintegrine-metalloprotease et procedes d&#39;utilisation
US20020102614A1 (en) Use of ZPR1 as a molecular probe for spinal muscular atrophy
JP2002514078A (ja) Ｆｔｈｍａ−０７０関連蛋白質ファミリーおよびｔ８５関連蛋白質ファミリーの新規分子ならびにそれらの使用
HUP0303905A2 (hu) KIAA-nukleinsavak és -polipeptidek prosztatarák diagnosztizálására és gyógykezelésére alkalmas expressziós analízise
JPH10337192A (ja) ヒトプロテインキナーゼｈｏａｃｆ７２
JPH07505524A (ja) Ｉｆｎ受容体認識因子，そのタンパク質配列および使用方法
US20160187340A1 (en) Compositions, Kits, and Methods for the Modulation of Immune Responses Using Galectin-1
JP2002509707A (ja) 肺腫瘍細胞を同定するための組成物および方法
JPWO2007026969A1 (ja) 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
EP1613769A1 (fr) Gene induit par l&#39;insuline utilise comme cible therapeutique dans le diabete
JP2004537277A (ja) 新規グルタミン酸レセプター調節タンパク質および核酸分子およびそれらの使用
JP2003530883A (ja) Ｎｆ−ａｔ相互作用タンパク質ｎｉｐ４５変異体の調節
US20040033226A1 (en) Osteopontin, oligodendrocytes and myelination
JP2005535313A (ja) オステオポンチン、オリゴデンドロサイトおよび髄鞘形成

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued